This is a randomized, placebo-controlled study to assess the safety, PK profile, and efficacy of COVI-AMG in subjects with COVID-19.
This is a multi-center, randomized, double-blind, placebo-controlled study followed by an
expansion cohort phase designed to investigate the safety, PK profile, and efficacy of a
single injection of COVI-AMG in outpatient subjects with COVID-19 but are not likely to
require hospital admission within 24 hours. Subjects will receive one of the following
treatments: 40 mg COVI-AMG, 100 mg COVI-AMG, 200 mg COVI-AMG, or placebo. Subjects will be
followed for 60 days after dosing.
Biological: COVI-AMG
COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb).
Other Name: STI-2020
Drug: Placebo
Diluent solution
Inclusion Criteria:
- Must be COVID-19 positive by RT-PCR or an equivalent test, using an appropriate sample
such as nasopharyngeal [NP], nasal, oropharyngeal [OP], or salivary) ≤ 72 hours prior
to randomization. A historical record of positive result from test conducted ≤ 72
hours prior to randomization is acceptable if it can be documented.
- Must be asymptomatic OR have mild symptoms but not requiring imminent (within 24h)
hospitalization.
- Must be willing and able to comply with all planned study procedures and be available
for all study visits and follow-up as required by this protocol.
- Subject or family member/caregiver must have provided written informed consent which
includes signing the institutional review board approved consent form prior to
participating in any study related activity.
Exclusion Criteria:
- Have a documented infection other than COVID-19 that requires systemic treatment or in
the investigator's opinion could interfere with the participant's safety or interfere
with the assessments if enrolled in the study.
- Have any medical condition that, in the Investigator's opinion, could adversely impact
safety.
- Be pregnant or lactating and breast feeding
- Has participated, or is participating, in a clinical research study evaluating
COVID-19 convalescent plasma, monoclonal antibodies (mAbs) against SARS-CoV-2, or
intravenous immunoglobulin (IVIG) within 3 months or less than 5 half-lives of the
investigational product (whichever is longer) prior to the screening visit. Note:
subjects who have been prescribed hydroxychloroquine or chloroquine with or without
azithromycin or other approved products for the off-label treatment of COVID-19 prior
to study enrollment may be included and may continue to receive these agents so long
as the dose remains stable. Additionally, any approved or authorized treatment (e.g.,
remdesivir, dexamethasone or treatments approved under an Emergency Use Authorization)
is allowed.
Mike Royal, MD, Study Director
Sorrento Therapeutics